News

This announcement follows the successful testing of DCR-PH1 in combination with Tekmira’s LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay

KTE-C19 is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient’s T cells to express a CAR that is designed to target CD19, a protein

Licensing provides RetroSense with worldwide access to key intellectual property which reinforces the Company’s dominant position in optogenetics for vision restoration. The licensed intellectual property is based on

Dr. Gareth Lavery, a prominent researcher with the University of Birmingham’s Centre for Endocrinology, Diabetes and Metabolism (CEDAM), has been awarded a prestigious Senior Fellowship in Basic Biomedical

The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML). "We are pleased to be granted

Teva’s Celecoxib is also indicated for the short-term management of moderate to severe acute pain in adults, in conditions such as musculoskeletal and/or soft tissue trauma including sprains,

Keryx is a biopharmaceutical firm focused on bringing new therapies to market for patients with renal disease. In September 2014, Auryxia was approved by the FDA to control

Under the deal, Allergan investors would receive $129.22 in cash and 0.3683 Actavis shares for each share of the Botox-maker’s common stock. The combination will create one of

Both the firms will explore the therapeutic potential of this new anti-PD-L1 antibody as a single agent as well as in various combinations with their broad portfolio of